Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

About this update from Vir Biotechnology, Inc.

SAN FRANCISCO --(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer , M.Sc ., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET . A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. View source version on businesswire.com : https://www.businesswire.com/news/home/20250520403573/en/ Media Corporate Communications, Vir Biotechnology [email protected] Investors Richard Lepke Senior Director, Investor Relations [email protected] Source: Vir Biotechnology, Inc.

View stock analysis, news, and events for Vir Biotechnology, Inc.